Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company’s Board of Directors BOSTON and LONDON, ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

TEDC1 and TEDC2, functions in generating centriolar triplet microtubules, and that this is crucial for the proper formation of centriolar subdomains and the stability of centrioles throughout the cell ...

ALE.P02 has a potentially first-in-class tubulin inhibitor payload, while ALE.P03 features a topoisomerase I inhibitor. The funding round was led by OrbiMed, with co-leads Novo Holdings and Jeito ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

Calcineurin inhibitors are topical and systemic immunosuppressants. They can help treat atopic dermatitis and autoimmune disorders such as lupus and psoriasis. They may also help prevent organ ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

We evaluated the effects of a novel tubulin-binding agent, plocabulin ... Combination with paclitaxel was not tested because paclitaxel and plocabulin share a similar mechanism of action (microtubule ...

Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their toxin classes, PH1 is a novel bi-functional payload that is designed to disrupt RNA splicing within cancer cells, ...